REC-1245
Solid tumors and lymphoma
REC-1245 is a highly potent RBM39 degrader being developed for the treatment of solid tumor indications and lymphoma, with multiple biomarkers being explored. RBM39 was identified using phenotypic insights by the Recursion OS, and is a novel target mimicking CDK12 loss. There are currently no RBM39 degraders approved by the FDA. Early preclinical data shows REC-1245 reduces viability in tumors characterized by replication stress and DNA repair vulnerabilities (DDR defects) across multiple solid tumor types, including MSI-H/dMMR, HRR altered cancers, and other tumors.
Learn more on clinicaltrials.gov
*Addressable incidence with biomarker-enriched solid tumors and other select histologies. All populations defined above are US and EU5 incidence unless otherwise noted. EU5 is defined as France, Germany, Italy, Spain, and UK.
